N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma

International Journal of Cancer

Volumn 127, Issue 1, 2010, Pages 148-159

  Fang, Meng ^a   Zhao, Yun Peng ^a   Zhou, Fei Guo ^a   Lu, Lun Gen ^b   Qi, Peng ^a   Wang, Hao ^c   Zhou, Kun ^b   Sun, Shu Han ^a   Chen, Cui Ying ^d   Gao, Chun Fang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Liver fibrosis; Marker; N glycan

Indexed keywords

GLYCAN; GLYCOPROTEIN; IMMUNOGLOBULIN G; POLYSACCHARIDE;

ADULT; ARTICLE; CANCER GROWTH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SEQUENCE; ELECTROPHORESIS; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; BLOOD; LIVER TUMOR; PATHOGENICITY; REPRODUCIBILITY; THEORETICAL MODEL; VIROLOGY;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; LIVER NEOPLASMS; MALE; MODELS, THEORETICAL; POLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 77953386036     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25030     Document Type: Article

References (42)

1. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-61.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
3. Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen MF. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol 2008;103:1421-6.
4. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
5. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseases. BMC Cancer 2008;18,8:200.
6. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007;13:1133-9.
7. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005;5:4581-8.
8. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005;41:634-42.
9. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF, Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-45.
10. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-82.
11. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74.
12. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, Poland DC, van Dijk W, Kuwano H, Kochibe N, Yazawa S. Alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004;101:2825-36.
13. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, Gu J, Kondo A, Taniguchi N, Miyoshi E. Fucosulation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Bio Chem 2006;281:29797-806.
14. Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. Clin Chem 2007;53:1254-63.
15. Kobata A, Amano J. Altered glycosylation of proteinss produced by malignent cells, and application for the diagnosis and immunotherapy of tumors. Immunol Cell Biol 2005;83:429-39.
16. Arnold JN, Saldova R, Hamid UM, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008;8:3284-93.
17. Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, Dinulescu DM, Pierce M. Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics 2008;8:3210-20.
18. Miyoshi E, Nakano M. Fucosylated hatoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008;8:3257-62.
19. Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, Sweeney CJ, Novotny MV. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res 2007;6:1822-32.
20. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA-sequencer based total serum protein glycomics. Nat Med 2004;10:429-34.
21. Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA-sequencing equipment. Nat Protoc 2006;1:397-405.
22. Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006;16:281-93.
23. Pilobello KT, Mahal LK. Lectin microarrays for glycoprotein analysis. Methods Mol Biol 2007;385:193-203.
24. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen CY. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46:1426-35.
25. Sobin LH, Wittekind CL, eds. TNM classification of malignant tumors, 6th edn. New York: Wiley, 2002.
26. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112-14.
27. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
28. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-23.
29. Marrero JA, Lok ASF. Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127:S113-S119.
30. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Glogi glycoprotein is a novel serum marker for hepatocellular carcinoma. Hepatology 2005;43:1007-12.
31. Tsai JF, Jeng JE, Chuang LY, You HL, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Yu ML, Dai CY. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scand J Gastroenterol 2005;40:68-75.
32. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006;26:4713-19.
33. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
34. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
35. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802-6.
36. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005;102:779-84.
37. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006;5:1957-67.
38. Vanhooren V, Liu XE, Franceschi C, Gao CF, Libert C, Contreras R, Chen C. Nglycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mech Ageing Dev 2009;120:92-7.
39. Arnold JN, Royle L, Dwek RA, Rudd PM, Sim RB. Human immunoglobulin glycosylation and the lectin pathway of complement activation. In: Axford JS, ed. Glycobiology and medicine, vol. 564. Netherlands: Springer, 2005. 27-43.
40. Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, Abdel-Hamid M, Gouda I, Ezzat S, Kyselova Z, Mechref Y, Novotny MV. Detection of hepatocellular carcinoma using glycomics analysis. Clin Cancer Res 2009;15:1808-13.
41. Chen C, Schimilovitz-Weiss H, Liu XE, Pappo O, Halpern M, Sulkes J, Braun M, Cohen M, Barak N, Tur-Kaspa R, Vanhooren V, Vlierberghe H, et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 2009;8:463-70.
42. Desmyter L, Fan YD, Praet M, Jaworski T, Vervecken W, De Hemptinne B, Contreras R, Chen C. Rating of CCl(4)-induced rat liver fibrosis by blood serum glycomics. J Gastroenterol Hepatol 2007;22:1148-54.